{"filing":{"accession_number":"0001193125-26-430997","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-10-26","report_date":"2026-10-24","primary_document":"clym-20261024.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526430997/clym-20261024.htm"},"events":[{"id":37763,"run_id":34802,"accession_number":"0001193125-26-430997","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Climb Bio announced initial Phase 2 clinical trial data for budoprutug in primary membranous nephropathy (pMN) and minimal change disease (MCD), presented at ASN Kidney Week 2026. The data demonstrate 70% mean PLA2R antibody reduction, 38% immunologic remission at 200 mg, generally good tolerability, and no serious adverse events, supporting dose escalation and representing a material clinical milestone for the company's lead program.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42587,"accession_number":"0001193125-26-430997","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Climb Bio disclosed initial Phase 2 clinical trial data for budoprutug in primary membranous nephropathy (pMN) and a case study in minimal change disease, presented at ASN Kidney Week 2026. The data demonstrate B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks, with generally good tolerability. This is a material clinical milestone for a clinical-stage biotech company's lead program, affecting investor assessment of the drug's therapeutic potential and development trajectory, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types—making it an operational/strategic milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:25:41.773531+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42588,"accession_number":"0001193125-26-430997","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Climb Bio announced initial Phase 2 clinical trial data for budoprutug in primary membranous nephropathy (pMN) and minimal change disease (MCD), presented at ASN Kidney Week 2026. The disclosure details efficacy endpoints (70% mean PLA2R antibody reduction, 38% immunologic remission at 200 mg), safety findings (generally well-tolerated, no serious adverse events), and pharmacokinetic insights supporting dose escalation. This is a material clinical milestone for a clinical-stage biotech company that would affect investor assessment of the drug's therapeutic potential and development trajectory, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other defined event types—making it an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:25:41.773531+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42587,"accession_number":"0001193125-26-430997","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Climb Bio disclosed initial Phase 2 clinical trial data for budoprutug in primary membranous nephropathy (pMN) and a case study in minimal change disease, presented at ASN Kidney Week 2026. The data demonstrate B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks, with generally good tolerability. This is a material clinical milestone for a clinical-stage biotech company's lead program, affecting investor assessment of the drug's therapeutic potential and development trajectory, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types—making it an operational/strategic milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:25:41.773531+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-10-26"},{"id":42588,"accession_number":"0001193125-26-430997","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Climb Bio announced initial Phase 2 clinical trial data for budoprutug in primary membranous nephropathy (pMN) and minimal change disease (MCD), presented at ASN Kidney Week 2026. The disclosure details efficacy endpoints (70% mean PLA2R antibody reduction, 38% immunologic remission at 200 mg), safety findings (generally well-tolerated, no serious adverse events), and pharmacokinetic insights supporting dose escalation. This is a material clinical milestone for a clinical-stage biotech company that would affect investor assessment of the drug's therapeutic potential and development trajectory, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other defined event types—making it an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:25:41.773531+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-10-26"}]}
